Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Scientists dig into why mantle cell lymphoma beats First-Line therapy

NCT ID NCT04882475

Knowledge-focused Sponsor: Fondazione Italiana Linfomi - ETS Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study examines stored tissue samples from 160 adults with mantle cell lymphoma whose cancer returned or didn't respond after initial chemotherapy and rituximab. Researchers will analyze the samples to identify genetic and cellular features linked to treatment resistance. The goal is to gather knowledge that could guide future therapies, but no new treatments are given to participants.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

160 people

The number who actually took part.

Started

Feb 2023

Expected to finish

Apr 2026

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Patients with Mantle Cell Lymphoma (MCL) who were relapsed or refractory to rituximab and chemotherapy containing induction regimens with curative intent.

Ages

18 to 80 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Patients with histologically documented diagnosis of Mantle Cell Lymphoma (MCL) as defined in the 2016 edition of the World Health Organization (WHO) classification, with available tissue for revision and additional studies; * Diagnosis of Mantle Cell Lymphoma (MCL) between 1st of January 2008 and 30th of June 2020; * Adults, 18-80 years at diagnosis; * Relapsed or refractory disease after rituximab and chemotherapy containing induction regimens with curative intent. * Treatment at relapse or progression on an intention-to-treat basis (ITT): at least one cycle of Chemo-immunotherapy (CIT), Bruton Tyrosine kinase inhibitors (BTKi), or alternative drugs combination; * Subject understanding and voluntarily signing an informed consent form approved by an Independent Ethics Committee (IEC), prior to the initiation of any study-specific procedures. Exclusion Criteria: * Unavailability of the samples requested by the study; * Any histology other than Mantle Cell Lymphoma (MCL); * Patients treated with front line regimens containing only rituximab or with palliative therapy; * Untreated patients; patients undergoing watchful waiting approach.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Mantle cell lymphoma are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

mantle cell lymphoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Mantle cell lymphoma

Contacts and locations

Locations

  • A.O. S. Croce e Carle

    Cuneo, 12100, Italy

  • A.O.U. Citta della Salute e della Scienza di Torino- Ematologia Universitaria

    Torino, Italy

  • AOU Integrata di Verona - U.O. Ematologia

    Verona, 37134, Italy

  • AOU Maggiore della Carità di Novara - SCDU Ematologia

    Novara, 28100, Italy

  • AOU Senese - U.O.C. Ematologia

    Siena, SI, 53100, Italy

  • AOU di Padova - Ematologia

    Padova, 35121, Italy

  • ASST Grande Ospedale Metropolitano Niguarda

    Milan, MI, 20162, Italy

  • ASST Spedali Civili di Brescia - Ematologia

    Brescia, Italy

  • Azienda Ospedaliera Universitaria Careggi- Unità funzionale di ematologia

    Florence, 50134, Italy

  • Azienda Sanitaria Universitaria Friuli Centrale (ASU FC) - SOC Clinica Ematologica

    Udine, Italy

  • Azienda Sanitaria Universitaria Giuliano Isontina (ASUGI) - SC Ematologia

    Trieste, Italy

  • Azienda Unitа Sanitaria Locale-IRCCS - Arcispedale Santa Maria Nuova - Ematologia - Ematologia

    Reggio Emilia, Italy

  • Centro Riferimento Oncologico - S.O.C. Oncologia Medica A

    Aviano, Italy

  • Ospedale Ca' Foncello - S.C di Ematologia

    Treviso, Italy

  • Ospedale Guglielmo da Saliceto - U.O.Ematologia

    Piacenza, 29121, Italy

  • ULSS 8 Berica - Ospedale S. Bortolo - Ematologia

    Vicenza, Italy

More trials for these conditions

Other studies related to the condition(s) this trial covers.